Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Cocrystal Pharma, Inc. on October 31, 2024. The Company is a biopharmaceutical entity incorporated in Delaware, with principal executive offices in Bothell, WA. Its common stock trades on The Nasdaq Capital Market under the symbol "COCP".
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain audited financial statements or quarterly financial results.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this filing. The report focuses on a specific regulatory disclosure event rather than financial performance trends.
Guidance, Outlook, and Management Commentary
Under Item 7.01 (Regulation FD Disclosure), the Company issued a press release on October 31, 2024, concerning certain of its antiviral product candidates and the viruses they target. The full text of this press release is furnished as Exhibit 99.1. No specific financial guidance, risk factors, or contingencies are detailed within the body of this 8-K form.
Key Facts for Investor Verification
- Review Exhibit 99.1 (Press Release) for specific details on the antiviral product candidates and their target viruses.
- Verify the trading status of COCP on The Nasdaq Capital Market following the disclosure.
- Note that this filing does not contain updated financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.